Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vicarious Surgical ( (RBOT) ) has shared an announcement.
On June 27, 2025, Vicarious Surgical Inc. held its annual meeting where stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the number of shares available for issuance. Additionally, the company’s Board of Directors approved changes to the non-employee director compensation policy, including new cash retainers and equity awards. The meeting also resulted in the election of Fuad Ahmad and Joseph Doherty to the Board, and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. These developments are expected to support Vicarious Surgical’s strategic goals, including advancing towards clinical trials and commercialization of its surgical platform.
The most recent analyst rating on (RBOT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Vicarious Surgical is a next-generation surgical robotics company, founded in 2014 and headquartered in Waltham, Massachusetts. The company is focused on developing disruptive technology to enhance surgical efficiency, improve patient outcomes, and reduce healthcare costs through its proprietary human-like surgical robots.
Average Trading Volume: 15,563
Technical Sentiment Signal: Strong Sell
Current Market Cap: $45.14M
Find detailed analytics on RBOT stock on TipRanks’ Stock Analysis page.